The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation ...
The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?
Investigators sought to determine if the gemcitabine intravesical system plus intravenous cetrelimab could improve survival for patients with muscle-invasive bladder cancer who did not receive radical ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...
A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...
Data from the IMvigor011 phase 3 study shows that adjuvant atezolizumab (Tecentriq) significantly boosts the reduction and clearance of circulating tumor DNA (ctDNA). Presented at ...
Enfortumab vedotin plus pembrolizumab significantly improves EFS and OS in cisplatin-ineligible MIBC patients, offering a new treatment option. The EV-303 trial is the first to show systemic treatment ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
Dr. Bill Salter, senior director of radiation oncology at the Huntsman Cancer Institute, gives a tour of the treatment room at the Sen. Orrin G. Hatch Center for Proton Therapy at the institute in ...
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...
Zacks Investment Research on MSN
RLMD stock surges 42% in a week: Here's what you should know
Shares of Relmada Therapeutics RLMD rallied 42% in a week after the company announced positive 12-month interim data from its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results